Evidence map›Paper›PMID 37128507›Full record

ArticleNeuro-oncology advances

Retrospective examination of pseudoprogression in

Ethan A Wetzel, Matthew J Farrell, Blaine S C Eldred, Vicki Liu, Ishan Saha, Serendipity Zapanta Rinonos, Terry Prins, Tie Li, Minsong Cao, John Hegde and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ethan A WetzelDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Matthew J FarrellDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Blaine S C EldredDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Vicki LiuDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Ishan SahaDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Serendipity Zapanta RinonosDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Terry PrinsDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Tie LiDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Minsong CaoDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
John HegdeDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Tania KaprealianDepartment of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Negar KhanlouDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Linda M LiauDepartment of Neurosurgery, University of California, Los Angeles, Los Angeles, CA, USA.
Phioanh Leia NghiemphuDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Timothy Francis CloughesyDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Robert A ChongDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.
Benjamin M EllingsonDepartment of Neurosurgery, University of California, Los Angeles, Los Angeles, CA, USA.
Albert LaiDepartment of Neurology, University of California, Los Angeles, Los Angeles, CA, USA.

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5M
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS T32 CA009056
6 · The paper itself

Abstract

Background: Tumor surveillance of isocitrate dehydrogenase ( Methods: We identified 587 Results: Fifty-six percent of patients developed CEnew (326/587); of these, 92/326 patients (28% of CEnew; 16% of all) developed PsP and 179/326 (55%) developed TP. All PsP patients had prior radiation, chemotherapy, or chemoradiotherapy. PsP was associated with longer overall survival (OS) versus TP patients and similar OS versus no CEnew. PsP differs from TP based on earlier time of onset (median 5.8 vs 17.4 months from treatment, Conclusion: PsP patients represented 28% of CEnew patients and 16% of all patients; PsP patients demonstrated superior outcomes to TP patients, and equivalent survival to patients without CEnew. PsP persists for <1 year, occurs after treatment, and differs from TP based on time of onset and radiographic features. Poor outcomes after CEnew are driven by TP.

Indexed as

contrast enhancementgliomaIDH1/2pseudoprogressionradiation necrosis

Identifiers

PMID37128507
PMCPMC10148681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.